apixaban vs edoxaban
Side-by-side comparison of apixaban and edoxaban Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Apixaban (Eliquis) is a medicine that helps prevent blood clots. It is used to lower the risk of stroke and other serious problems caused by blood clots.
Savaysa is a medicine that helps to prevent blood clots. It is used to lower the chance of stroke in people with an irregular heartbeat (atrial fibrillation) and to treat blood clots in the legs or lungs.
Apixaban is used to lower the chance of stroke in people with an irregular heartbeat called atrial fibrillation. It also prevents blood clots in the legs (deep vein thrombosis or DVT) that can happen after hip or knee replacement surgery. Apixaban is also used to treat DVT and lung clots (pulmonary embolism or PE), and to prevent them from coming back.
Savaysa is used to lower the risk of stroke and blood clots in people with nonvalvular atrial fibrillation, a type of irregular heartbeat. It is also used to treat blood clots in the deep veins of your legs (DVT) or in your lungs (PE). You will likely need to take another medicine to prevent blood clots for 5 to 10 days before starting Savaysa for DVT or PE.
Apixaban is a type of drug called a factor Xa inhibitor. It works by blocking a substance in the blood that helps clots form. This helps to keep your blood flowing smoothly.
Savaysa is a factor Xa inhibitor. This means it blocks a substance in your blood called factor Xa. By blocking factor Xa, Savaysa helps to prevent blood from clotting.
- • Bleeding more easily (like nosebleeds or heavier periods)
- • Bruising more easily
- • Bleeding
- • Anemia (low red blood cells)
- • Rash
- • Abnormal liver function tests
- Irregular heartbeat 3,970
- Shortness of breath 3,598
- Stroke 3,508
- Blood clot 2,806
- Using the medicine for something it's not approved for 2,693
No adverse event reports.
Apixaban has two important warnings. First, stopping apixaban too early can raise your risk of blood clots. Don't stop taking it without talking to your doctor. Second, if you have spinal anesthesia or a spinal puncture while taking apixaban, you could get a blood clot around your spine, which can cause long-term paralysis.
Savaysa may not work as well to prevent strokes if you have atrial fibrillation and your kidneys are working very well (CrCl > 95 mL/min). If you stop taking Savaysa too soon, you have a higher risk of blood clots or stroke. If you get medicine injected into your spine while taking Savaysa, it could cause bleeding around your spine, which can lead to paralysis.
Apixaban is not recommended during pregnancy because it may increase the risk of bleeding during pregnancy and delivery. Talk to your doctor about the risks and benefits of taking apixaban if you are breastfeeding. You may need to stop taking the drug or stop nursing.
Tell your doctor if you are pregnant or plan to become pregnant. Savaysa may increase the risk of bleeding in the fetus. Do not breastfeed while taking Savaysa.
Also Compare — Nearby Drugs
Compare apixaban with
Compare edoxaban with
How to Read This apixaban vs edoxaban Comparison
apixaban is classified in the Direct Oral Anticoagulant (Factor Xa Inhibitor) drug class, while edoxaban sits within the Direct Oral Anticoagulant (Factor Xa Inhibitor) class. Because both drugs share the same classification, they are often considered interchangeable in theory — but clinical outcomes rarely track that cleanly. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, apixaban has 16,575 submissions while edoxaban has 0. Those figures reflect cumulative reporting volume — not per-patient risk — so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between apixaban and edoxaban — always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.